Fulgent Genetics (FLGT) CSO has 1,645 shares withheld for tax obligations

Rhea-AI Filing Summary

Fulgent Genetics, Inc. Chief Scientific Officer Hanlin Gao reported a routine tax-related share disposition. On the vesting of restricted stock units assumed in a prior merger, 1,645 shares of common stock were withheld to cover tax withholding obligations at $16.31 per share.

Following this tax-withholding event, Gao directly holds 993,007 shares of Fulgent Genetics common stock. This withholding is an administrative mechanism tied to equity compensation and does not represent an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gao Hanlin

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	1,645	$16.31	$27K

Holdings After Transaction: Common Stock — 993,007 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares withheld for taxes: 1,645 shares Tax-withholding share value: $16.31 per share Shares owned after transaction: 993,007 shares

3 metrics

Shares withheld for taxes 1,645 shares Tax-withholding disposition on RSU vesting

Tax-withholding share value $16.31 per share Valuation price used for withheld shares

Shares owned after transaction 993,007 shares Direct ownership following tax withholding

Key Terms

restricted stock units, Agreement and Plan of Merger, tax withholding obligations

3 terms

restricted stock units financial

"tax withholding obligations that arose upon the vesting of certain restricted stock units assumed"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Agreement and Plan of Merger financial

"assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022"

An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.

tax withholding obligations financial

"shares were withheld from the reporting person to satisfy the tax withholding obligations that arose"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gao Hanlin

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CALIFORNIA 91731

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/26/2026		F		1,645(1)	D	$16.31	993,007	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.

	/s/ Paul Kim as Attorney-in-Fact	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Fulgent Genetics (FLGT) report for Hanlin Gao?

Fulgent Genetics reported that Chief Scientific Officer Hanlin Gao had 1,645 shares withheld to cover tax obligations on vested restricted stock units. This Form 4 reflects a tax-withholding disposition, not an open-market trade, and is part of routine equity compensation administration.

How many Fulgent Genetics (FLGT) shares were withheld for taxes in this Form 4?

The Form 4 shows that 1,645 shares of Fulgent Genetics common stock were withheld to satisfy tax withholding obligations. These shares relate to the vesting of restricted stock units and were not sold on the open market, but retained by the company for tax payment.

At what price were Hanlin Gao’s withheld FLGT shares valued in the transaction?

The withheld 1,645 Fulgent Genetics shares were valued at $16.31 per share for the tax-withholding disposition. This price is used to calculate the value applied toward Gao’s tax obligations arising from the vesting of previously granted restricted stock units.

How many Fulgent Genetics (FLGT) shares does Hanlin Gao own after this filing?

After the tax-withholding disposition, Hanlin Gao directly owns 993,007 shares of Fulgent Genetics common stock. This figure reflects his holdings following the withholding of 1,645 shares for taxes related to the vesting of certain restricted stock unit awards.

Was this FLGT insider transaction an open-market sale by Hanlin Gao?

No. The transaction is classified as a tax-withholding disposition, not an open-market sale. Shares were withheld by Fulgent Genetics to cover Gao’s tax obligations when restricted stock units vested, making this a routine administrative event tied to equity compensation.

What is the origin of the restricted stock units in this Fulgent Genetics Form 4?

The restricted stock units originated from awards assumed under an Agreement and Plan of Merger dated November 7, 2022, involving Fulgent Genetics and Fulgent Pharma Holdings. The vesting of those assumed units triggered the tax-withholding disposition disclosed in this Form 4.